Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 56

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 56
---
.70

			Expired

			(35,674
			)

			33.18

			24.63

			Balance - June 30, 2024

			383,040

			$
			24.93

			$
			18.33

13

During the three and nine months ended June 30, 2025, there were no employee or director options granted. During the three and nine months ended June 30, 2024, there were 500 employee options granted and no director options granted. The options have a term of 10 years and an exercise price equal to the Nasdaq closing price on the grant date.

The weighted average contractual life remaining on the outstanding options at June 30, 2025 is 72 months.

The following table summarizes information about the options under the 2019 Plan outstanding and exercisable at June 30, 2025:

			Number of Options (#) 

			Exercisable at
			June 30, 2025 (#)

			Range of Exercise Prices 

			Expiry Dates

			37,719

			37,719

			C$
			15.12

			 August 2027 - Dec 2028

			43,031

			43,031

			$
			22.12

			Feb 2030

			51,006

			51,006

			$
			52.08 - 56.49

			September 2030 - Oct 2030

			79,651

			79,651

			$
			36.75 - 40.18

			March 2025 - Sep 2031

			56,865

			56,865

			$
			25.97

			March 2025 - Feb 2032

			109,963

			84,346

			$
			4.10 - 10.01

			March 2025 - Oct 2033

			378,235

			352,618

The options exercisable at June 30, 2025 had a weighted average exercise price of $25.93, no intrinsic value and a weighted average remaining life of 72 months. There were 25,617 options at June 30, 2025 that had not vested